Leczenie otyłości w świetle aktualnych wytycznych dotyczących prewencji chorób sercowo-naczyniowych – część II Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
cze 30, 2023
Słowa kluczowe:
otyłość, nadwaga, cukrzyca, masa ciała, BMI, insulinooporność
##plugins.themes.bootstrap3.article.main##
Abstrakt
Istotą otyłości jest zwiększenie ilości żółtej tkanki tłuszczowej zbudowanej z adipocytów wypełnionych triacyloglicerolami. Przed rozpoczęciem leczenia ważne jest określenie obecności elementów zespołu metabolicznego i rozróżnienie od insulinooporności. Poza dietą, aktywnością fizyczną i ewentualnymi operacjami bariatrycznymi (omówionymi w pierwszej części artykułu) II linię leczenia stanowi farmakoterapia. Niektóre leki stosowane w innych wskazaniach również mogą się przyczynić do redukcji masy ciała – leki działające ośrodkowo i leki wykorzystywane w leczeniu cukrzycy. W celu uzyskania satysfakcjonujących wyników leczenia istotne są zrozumienie mechanizmów prowadzących do otyłości oraz znajomość metod walki z tą chorobą.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Knapik, K., Tyszkiewicz, J., & Lewandowski, J. (2023). Leczenie otyłości w świetle aktualnych wytycznych dotyczących prewencji chorób sercowo-naczyniowych – część II. Medycyna Faktów , 16(2(59), 151-157. https://doi.org/10.24292/01.MF.0223.04
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Sawicki W, Malejczyk J. Tkanka tłuszczowa. In: Histologia. 6th ed. PZWL, Warszawa 2021: 173-4.
2. De Souza RJ, Mente A, Maroleanu A et al. Intake of saturated and trans unsaturated fatty acids and risk of all-cause mortality, cardiovascular disease, and type 2 diabetes: systematic review and meta-analysis of observational studies. BMJ. 2015; 351: h3978.
3. Sonestedt E, Ericson U, Gullberg B et al. Do both heterocyclic amines and omega-6 polyunsaturated fatty acids contribute to the incidence of breast cancer in postmenopausal women of the Malmö diet and cancer cohort? Int J Cancer. 2008; 123(7): 1637-43.
4. Berquin IM, Min Y, Wu R et al. Modulation of prostate cancer genetic risk by omega-3 and omega-6 fatty acids. J Clin Invest. 2007; 117(7): 1866-75.
5. Mayans L. Metabolic Syndrome: Insulin Resistance and Prediabetes. FP Essent. 2015; 435: 11-6.
6. Gartner LP, Hiatt JL. Connective Tissue. In: Cell Biology and Histology. 7th ed. Wolters Kluwer, Warszawa 2015: 94-102.
7. Tuomilehto J, Lindström J, Eriksson JG et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001; 344(18): 1343-50.
8. Diabetes Prevention Program (DPP), NIDDK (access: 11.02.2023).
9. Xenical, European Medicines Agency (access: 6.10.2022).
10. Sjöström L, Rissanen A, Andersen T et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet. 1998; 352(9123): 167-72.
11. Naltrexone/bupropion for obesity. Drug Ther Bull. 2017; 55(11): 126-9.
12. Greenway FL, Fujioka K, Plodkowski RA et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010; 376(9741): 595-605.
13. Mehta A, Marso SP, Neeland IJ. Liraglutide for weight management: a critical review of the evidence. Obes Sci Pract. 2017; 3(1): 3-14.
14. Glucagon-like peptide 1-based therapies for the treatment of type 2 diabetes mellitus – Up-ToDate (access: 11.02.2023).
15. Wilding JPH, Batterham RL, Calanna S et al. Once-Weekly Semaglutide in Adults with Over-weight or Obesity. N Engl J Med. 2021; 384(11): 989-1002.
16. Moreno JL, Willett KC, Desilets AR. Exenatide as a novel weight loss modality in patients without diabetes. Ann Pharmacother. 2012; 46(12): 1700-6.
17. Kyrillos J. Semaglutide 2.4-mg injection as a novel approach for chronic weight management. Am J Manag Care. 2022; 28(15 suppl): S297-306.
18. Chao AM, Tronieri JS, Amaro A et al. Semaglutide for the treatment of obesity. Trends Cardiovasc Med. 2023; 33(3): 159-66.
19. de Souza A. Metformin: From medieval age to new therapeutic targets. Int J Diabetes Dev Ctries. 2008; 28(1): 31.
20. Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia. 2017; 60(9): 1577.
21. Yerevanian A, Soukas AA. Metformin: Mechanisms in Human Obesity and Weight Loss. Curr Obes Rep. 2019; 8(2): 156.
22. Malin SK, Kashyap SR. Effects of metformin on weight loss: potential mechanisms. Curr Opin Endocrinol Diabetes Obes. 2014; 21(5): 323-9.
23. Bray GA, Edelstein SL, Crandall JP et al. Long-term safety, tolerability, and weight loss associated with metformin in the diabetes prevention program outcomes study. Diabetes Care. 2012; 35(4): 731-7.
24. Pu R, Shi D, Gan T et al. Effects of metformin in obesity treatment in different populations: a meta-analysis. Ther Adv Endocrinol Metab. 2020; 11: 2042018820926000.
25. Kruse T, Lerche Hansen J, Dahl K et al. Development of Cagrilintide, a Long-Acting Amylin Analogue. J Med Chem. 2021; 64(15): 11183-94.
26. Kramer CK, Leitão CB, Pinto LC et al. Efficacy and safety of topiramate on weight loss: a meta-analysis of randomized controlled trials. Obes Rev. 2011; 12(5): e338-47.
27. Smith SR, Weissman NJ, Anderson CM et al. Multicenter, Placebo-Controlled Trial of Lorcaserin for Weight Management. N Engl J Med. 2010; 363(3): 245-56.
28. Edelman S, Maier H, Wilhelm K. Pramlintide in the treatment of diabetes mellitus. BioDrugs. 2008; 22(6): 375-86.
29. Jastreboff AM, Aronne LJ, Ahmad NN et al. SURMOUNT-1 Investigators. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022; 387(3): 205-16.
30. Capristo E, Maione A, Lucisano G et al. Effects of weight loss medications on mortality and cardiovascular events: A systematic review of randomized controlled trials in adults with over-weight and obesity. Nutr Metab Cardiovasc Dis. 2021; 31(9): 2587-95.
31. Huixing L, Di F, Daoquan P. Effect of Glucagon-like Peptide-1 Receptor Agonists on Progno-sis of Heart Failure and Cardiac Function: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Clin Ther. 2023; 45(1): 17-30.
2. De Souza RJ, Mente A, Maroleanu A et al. Intake of saturated and trans unsaturated fatty acids and risk of all-cause mortality, cardiovascular disease, and type 2 diabetes: systematic review and meta-analysis of observational studies. BMJ. 2015; 351: h3978.
3. Sonestedt E, Ericson U, Gullberg B et al. Do both heterocyclic amines and omega-6 polyunsaturated fatty acids contribute to the incidence of breast cancer in postmenopausal women of the Malmö diet and cancer cohort? Int J Cancer. 2008; 123(7): 1637-43.
4. Berquin IM, Min Y, Wu R et al. Modulation of prostate cancer genetic risk by omega-3 and omega-6 fatty acids. J Clin Invest. 2007; 117(7): 1866-75.
5. Mayans L. Metabolic Syndrome: Insulin Resistance and Prediabetes. FP Essent. 2015; 435: 11-6.
6. Gartner LP, Hiatt JL. Connective Tissue. In: Cell Biology and Histology. 7th ed. Wolters Kluwer, Warszawa 2015: 94-102.
7. Tuomilehto J, Lindström J, Eriksson JG et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001; 344(18): 1343-50.
8. Diabetes Prevention Program (DPP), NIDDK (access: 11.02.2023).
9. Xenical, European Medicines Agency (access: 6.10.2022).
10. Sjöström L, Rissanen A, Andersen T et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet. 1998; 352(9123): 167-72.
11. Naltrexone/bupropion for obesity. Drug Ther Bull. 2017; 55(11): 126-9.
12. Greenway FL, Fujioka K, Plodkowski RA et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010; 376(9741): 595-605.
13. Mehta A, Marso SP, Neeland IJ. Liraglutide for weight management: a critical review of the evidence. Obes Sci Pract. 2017; 3(1): 3-14.
14. Glucagon-like peptide 1-based therapies for the treatment of type 2 diabetes mellitus – Up-ToDate (access: 11.02.2023).
15. Wilding JPH, Batterham RL, Calanna S et al. Once-Weekly Semaglutide in Adults with Over-weight or Obesity. N Engl J Med. 2021; 384(11): 989-1002.
16. Moreno JL, Willett KC, Desilets AR. Exenatide as a novel weight loss modality in patients without diabetes. Ann Pharmacother. 2012; 46(12): 1700-6.
17. Kyrillos J. Semaglutide 2.4-mg injection as a novel approach for chronic weight management. Am J Manag Care. 2022; 28(15 suppl): S297-306.
18. Chao AM, Tronieri JS, Amaro A et al. Semaglutide for the treatment of obesity. Trends Cardiovasc Med. 2023; 33(3): 159-66.
19. de Souza A. Metformin: From medieval age to new therapeutic targets. Int J Diabetes Dev Ctries. 2008; 28(1): 31.
20. Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia. 2017; 60(9): 1577.
21. Yerevanian A, Soukas AA. Metformin: Mechanisms in Human Obesity and Weight Loss. Curr Obes Rep. 2019; 8(2): 156.
22. Malin SK, Kashyap SR. Effects of metformin on weight loss: potential mechanisms. Curr Opin Endocrinol Diabetes Obes. 2014; 21(5): 323-9.
23. Bray GA, Edelstein SL, Crandall JP et al. Long-term safety, tolerability, and weight loss associated with metformin in the diabetes prevention program outcomes study. Diabetes Care. 2012; 35(4): 731-7.
24. Pu R, Shi D, Gan T et al. Effects of metformin in obesity treatment in different populations: a meta-analysis. Ther Adv Endocrinol Metab. 2020; 11: 2042018820926000.
25. Kruse T, Lerche Hansen J, Dahl K et al. Development of Cagrilintide, a Long-Acting Amylin Analogue. J Med Chem. 2021; 64(15): 11183-94.
26. Kramer CK, Leitão CB, Pinto LC et al. Efficacy and safety of topiramate on weight loss: a meta-analysis of randomized controlled trials. Obes Rev. 2011; 12(5): e338-47.
27. Smith SR, Weissman NJ, Anderson CM et al. Multicenter, Placebo-Controlled Trial of Lorcaserin for Weight Management. N Engl J Med. 2010; 363(3): 245-56.
28. Edelman S, Maier H, Wilhelm K. Pramlintide in the treatment of diabetes mellitus. BioDrugs. 2008; 22(6): 375-86.
29. Jastreboff AM, Aronne LJ, Ahmad NN et al. SURMOUNT-1 Investigators. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022; 387(3): 205-16.
30. Capristo E, Maione A, Lucisano G et al. Effects of weight loss medications on mortality and cardiovascular events: A systematic review of randomized controlled trials in adults with over-weight and obesity. Nutr Metab Cardiovasc Dis. 2021; 31(9): 2587-95.
31. Huixing L, Di F, Daoquan P. Effect of Glucagon-like Peptide-1 Receptor Agonists on Progno-sis of Heart Failure and Cardiac Function: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Clin Ther. 2023; 45(1): 17-30.